| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Net revenues | 227,813 | 211,371 | 148,332 | 138,040 |
| Cost of sales (excluding depreciation and amortization) | 93,389 | 74,615 | 63,075 | 57,698 |
| Research and development | 12,304 | 16,535 | 10,128 | 7,296 |
| Gain on sale of building | - | 0 | - | - |
| Selling, general, and administrative | 76,656 | 81,771 | 79,075 | 52,821 |
| Depreciation and amortization | 22,632 | 23,281 | 15,748 | 14,697 |
| Contingent consideration fair value adjustment | -14,470 | 1,277 | 825 | 359 |
| Loss (gain) on disposal of assets | -295 | - | - | - |
| Intangible asset impairment charge | 767 | - | - | - |
| Total operating expenses, net | 191,573 | 197,479 | 168,851 | 132,871 |
| Operating income (loss) | 36,240 | 13,892 | -20,519 | 5,169 |
| Unrealized gain on investment in equity securities | 3,140 | 332 | 1,355 | -2,712 |
| Interest expense, net | -4,727 | -5,438 | -2,331 | -4,656 |
| Other (expense) income, net | -853 | 1,739 | -2,535 | -88 |
| Loss on extinguishment of debt | 0 | - | -7,468 | - |
| Income (loss) before income tax expense (benefit) | 33,800 | 10,525 | -31,498 | -2,287 |
| Income tax expense (benefit) | 7,183 | 1,976 | -7,332 | - |
| Net income (loss) | 26,617 | 8,549 | -24,166 | -2,287 |
| Dividends on series a convertible preferred stock | 344 | 407 | 406 | 407 |
| Net income (loss) available to common shareholders | 26,273 | 8,142 | -24,572 | -2,694 |
| Basic income (loss) per share(in dollars per share) | 1.19 | 0.37 | -1.27 | -0.14 |
| Basic weighted-average shares outstanding (in shares) | 20,074,000 | 19,834,000 | 19,404,000 | 19,321,000 |
| Diluted income (loss) per share (in dollars per share) | 1.13 | 0.36 | -1.27 | -0.14 |
| Diluted weighted-average shares outstanding (in shares) | 21,093,000 | 20,308,000 | 19,404,000 | 19,321,000 |
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)